Acromicric dysplasia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:969OMIM:102370Q77.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Acromicric dysplasia is a rare skeletal disorder characterized by severe short stature, short hands and feet, and mild facial dysmorphism. The condition is caused by mutations in the FBN1 gene (fibrillin-1), which plays a critical role in the formation of extracellular matrix microfibrils. Acromicric dysplasia belongs to a spectrum of acromelic dysplasias that also includes geleophysic dysplasia and Weill-Marchesani syndrome, all of which can result from specific mutations in FBN1 affecting the TGF-beta signaling pathway. Key clinical features include proportionate short stature that becomes apparent in childhood, with adult height typically ranging from 130 to 150 cm. Affected individuals have characteristically short, stubby hands and feet (brachydactyly) with cone-shaped epiphyses visible on X-ray. Facial features may include a round face, well-defined eyebrows, long eyelashes, a small nose with anteverted nostrils, a long philtrum, and thick lips. Joint limitations, particularly of the hands and wrists, are common and may worsen over time. Mild skin thickening on the hands and forearms, as well as hoarse voice, have also been reported. Internal organ involvement is generally mild compared to geleophysic dysplasia, though some patients may develop mild cardiac valve abnormalities or recurrent respiratory issues related to tracheal narrowing. There is currently no specific cure or targeted therapy for acromicric dysplasia. Management is supportive and multidisciplinary, focusing on orthopedic monitoring, management of joint stiffness through physical therapy, and surveillance for potential cardiac or respiratory complications. Growth hormone therapy has been attempted in some cases but generally shows limited efficacy. Carpal tunnel syndrome may develop and require surgical intervention. Regular follow-up with specialists in genetics, orthopedics, cardiology, and pulmonology is recommended to monitor for complications and optimize quality of life.

Clinical phenotype terms— hover any for plain English:

Ovoid vertebral bodiesHP:0003300Fifth metacarpal with ulnar notchHP:0005900
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Acromicric dysplasia.

View clinical trials →

No actively recruiting trials found for Acromicric dysplasia at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Acromicric dysplasia community →

No specialists are currently listed for Acromicric dysplasia.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Acromicric dysplasia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Acromicric dysplasiaForum →

No community posts yet. Be the first to share your experience with Acromicric dysplasia.

Start the conversation →

Latest news about Acromicric dysplasia

No recent news articles for Acromicric dysplasia.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Acromicric dysplasia

What is Acromicric dysplasia?

Acromicric dysplasia is a rare skeletal disorder characterized by severe short stature, short hands and feet, and mild facial dysmorphism. The condition is caused by mutations in the FBN1 gene (fibrillin-1), which plays a critical role in the formation of extracellular matrix microfibrils. Acromicric dysplasia belongs to a spectrum of acromelic dysplasias that also includes geleophysic dysplasia and Weill-Marchesani syndrome, all of which can result from specific mutations in FBN1 affecting the TGF-beta signaling pathway. Key clinical features include proportionate short stature that becomes

How is Acromicric dysplasia inherited?

Acromicric dysplasia follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Acromicric dysplasia typically begin?

Typical onset of Acromicric dysplasia is childhood. Age of onset can vary across affected individuals.